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Abstract
Background: Our objective was to describe the characteristics of acute and established HIV infections diagnosed
in the Canadian province of British Columbia. Province-wide HIV testing and surveillance data were analyzed to
inform recommendations for targeted use of screening algorithms to detect acute HIV infections.
Methods: Acute HIV infection was defined as a confirmed reactive HIV p24 antigen test (or HIV nucleic acid test), a
non-reactive or reactive HIV EIA screening test and a non-reactive or indeterminate Western Blot. Characteristics of
unique individuals were identified from the British Columbia HIV/AIDS Surveillance System. Primary drug resistance
and HIV subtypes were identified by analyzing HIV pol sequences from residual sera from newly infected
individuals.
Results: From February 2006 to October 2008, 61 individuals met the acute HIV infection case definition,
representing 6.2% of the 987 newly diagnosed HIV infections during the analysis period. Acute HIV infection cases
were more likely to be men who have sex with men (crude OR 1.71; 95% CI 1.01-2.89], to have had a documented
previous negative HIV test result (crude OR 2.89; 95% CI 1.52-5.51), and to have reported a reason for testing due
to suspected seroconversion symptoms (crude OR 5.16; 95% CI 2.88-9.23). HIV subtypes and rates of transmitted
drug resistance across all classes of drugs were similar in persons with both acute and established HIV infections.
Conclusions: Targeted screening to detect acute HIV infection is a logical public health response to the HIV
epidemic. Our findings suggest that acute HIV infection screening strategies, in our setting, are helpful for early
diagnosis in men who have sex with men, in persons with seroconversion symptoms and in previously negative
repeat testers.
Background
Acute HIV infection (AHI) has received increasing
attention because of its substantial contribution to
ongoing HIV transmission [1-6], which has prompted
initiatives to identify AHI in order to inform persons of
their HIV-positive status during this highly infectious
phase. This has been shown to lead to individual beha-
viour change, which may limit further spread of infec-
tion [7]; knowledge of HIV status has been shown to
have a marked effect on reducing high-risk sexual beha-
viour [8].
Current second- and third-generation HIV screening
tests have limited ability to detect AHI cases during the
seroconversion period. This is also true in settings that
utilize rapid or point-of-care HIV antibody testing [9].
Fourth-generation HIV screening tests, which detect
both anti-HIV and p24 antigen, have reduced the sero-
conversion window period [10], and studies have also
demonstrated the utility of combining third-generation
screening immunoassays with pooled HIV nucleic acid
testing (NAT) to shorten the window period between
exposure and detection of HIV infection [11]. The
North Carolina, US, state programme, which uses
pooled NAT for universal screening [12], has not been
widely extended to other populations with low HIV pre-
valence because of high costs. However, there is an
emerging consensus supporting the use of AHI screen-
ing in settings with high HIV incidence [13,14]. A cut-
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antibody negative samples has been suggested as a guide
to select populations to use this approach [15].
The use of pooled NAT has detected between 3.9%
and 10.5% additional HIV infections when compared
with second- or third-generation antibody screening
tests in sexually transmitted infection clinics and sites
patronized by men who have sex with men (MSM)
[11,16]. However, robust population data to inform cri-
teria for targeted AHI screening using pooled NAT are
lacking. In the Canadian province of British Columbia
(BC), the majority of HIV tests are conducted in a single
laboratory, which enables analysis of provincial data to
inform targeted AHI screening. The BC Public Health
Microbiology and Reference Laboratory uses third-gen-
eration antibody screening, with additional testing for
p24 antigen to resolve indeterminate HIV serology, thus
enabling a comprehensive review of a series of probable
AHIs identified during routine screening.
We compared characteristics of AHIs with all other
newly diagnosed HIV infections over a 32-month period
to identify criteria to inform enhanced screening strate-
gies for AHI. We also compared HIV subtype distribu-
tion and transmitted drug resistance (TDR) patterns
between AHI and established HIV-infected individuals
over the same time period.
Methods
Approximately 95% of HIV antibody screening in BC
occurs at the Provincial Public Health Microbiology and
Reference Laboratory at the BC Centre for Disease Con-
trol (BCCDC). Reactive HIV screening tests performed
at other BC laboratories and point-of-care sites are
referred to the BCCDC, where all HIV confirmatory
testing is performed. The current testing algorithm con-
sists of a third-generation enzyme immunoassay (EIA)
test (Siemens ADVIA™ Centaur HIV-1/O/2) with con-
firmation of EIA reactive specimens by HIV-1 Western
Blot (WB) (BioRad Genetic Systems™ HIV-1 Western
Blot). EIA reactive specimens, with a non-reactive or
indeterminate WB, undergo reflex testing for HIV-1 p24
antigen (Biomérieux Vironostika™ HIV-1 Antigen) to
help resolve the HIV serological status. p24 antigen
reactive specimens are confirmed by a neutralization
procedure or by follow-up HIV-1 NAT testing (Roche
AMPLICOR™HIV-1 DNA Test, v.1.5).
Province-wide HIV testing and surveillance data from
February 2006 to October 2008 were analyzed to inform
recommendations for targeted use of AHI screening
algorithms for a Canadian Institutes of Health Research-
funded study of acute HIV infection. Ethical approval
was obtained from the University of British Columbia
Clinical Research Ethics Board (UBC-CREB).
The case definition for presumptive AHI included a
reactive p24 antigen (confirmed by neutralization or by
follow-up HIV-1 NAT) together with a non-reactive or
reactive EIA, followed by a non-reactive or indetermi-
nate WB. Presumptive AHI cases needed to meet the
public health surveillance case definition for HIV infec-
tion, which requires confirmation by follow-up serologic
testing or viral load and/or CD4 counts compatible with
HIV infection. As the serologic pattern of presumptive
AHI cases may be similar to individuals with late-stage
HIV infection (i.e., p24 antigen reactive, indeterminate
WB), presumptive AHI cases with a reported diagnosis
of AIDS within one year were treated as established
infections. All other HIV infections diagnosed during
the study period were considered to have established
HIV infection. All newly diagnosed HIV cases were
included in the analysis, i.e., there were no age-based
exclusions. Routine demographic information on AHI
and established cases was retrieved from the BC HIV/
AIDS Surveillance System, which captures past HIV
testing history, risk exposure, reason for testing, and
geographic location of the test provider. Risk exposure
data are not collected from individuals at the time of
HIV testing.
Primary drug resistance and HIV subtype determina-
tion is routinely performed by the National HIV and
Retrovirology Laboratories in Ottawa using residual sera
from newly diagnosed HIV infections, as part of the
UBC-CREB-approved Canadian HIV Strain and Drug
Resistance Surveillance Program. Transmitted drug
resistance (TDR) mutations within the protease gene
and the first 236 codons of reverse transcriptase, along
with subtype, were determined using the Stanford
HIVdb Calibrated Population Resistance Tool v.5 beta
[http://cpr.stanford.edu/cpr/servlet/CPR], accessed prior
to 17 February 2010 [17]. Sequences lacking TDR muta-
tions were classified as wild type.
Demographics, exposure category, HIV testing history,
HIV subtype and TDR rates for individuals with AHI
and established HIV infection were compared by bivari-
ate analysis in SPSS (v.14.0.2). Independent sample t-
tests and Pearson’s Chi-square and Fisher’s Exact Test
were calculated as appropriate. Univariate and multivari-
able logistic regression analyses were used to identify
factors associated with AHI. Variables (gender, MSM,
history of prior negative test and presence of AHI symp-
toms) were chosen in the multivariable model based on
statistical significance and clinical relevance. Odds ratios
(ORs) and 95% confidence intervals (CIs) were obtained
from the logistic regression model, and reported as a
measure of association.
Results
A total of 987 new HIV infections were identified during
the 32-month period. Of these, 61 (6.2%) met the case
definition for AHI. Three additional cases met the
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laboratory diagnostic criteria for presumptive AHI, but
were not counted as new HIV infections as no confir-
matory testing was done, as required by the surveillance
case definition. Two other presumptive AHI cases were
counted as established infections because they had AIDS
case reports within 12 months of diagnosis. Of the 61
confirmed AHI cases, four had a non-reactive third-gen-
eration EIA and were tested for HIV-1 p24 antigen on
request from the healthcare provider because of symp-
toms suggestive of a seroconversion illness. All the
remaining specimens were third-generation EIA reactive,
but the WB on the same specimen was either non-reac-
tive or indeterminate.
Table 1 shows the demographic characteristics, HIV
subtype and TDR results for the 61 AHI and 926 estab-
lished HIV cases. While we did not find a statistically
significant difference with respect to sex, the univariate
analysis demonstrated that AHI cases had a greater
odds of being MSM (crude OR 1.71; 95% CI 1.01-2.89),
to have had a documented previous negative HIV test
result (crude OR 2.89; 95% CI 1.52-5.51), and to have
reported a reason for testing due to seroconversion
symptoms (crude OR 5.16; 95% CI 2.88-9.23). When
these variables, together with sex (male or female), were
included in a logistic regression model, MSM was no
longer significantly associated with AHI (Table 2). Rea-
son for testing due to seroconversion symptoms
(adjusted OR 4.35; 95% CI 2.39, 7.91) and a documented
previous negative HIV test (adjusted OR 2.59; 95% CI
1.35, 4.99) remained significantly associated with AHI.
HIV genotypes and drug resistance mutations were
obtained for all new infections for which there was suffi-
cient residual sample volume and from which HIV RNA
could be amplified, i.e., 49 of 61 AHIs and 686 of 926
established infections (Table 1). There was no statistically
significant difference in the proportions of HIV subtypes
between AHIs and established cases. HIV-1 subtype B has
accounted for more than 90% of all new HIV infections in
BC since the Canadian HIV Strain and Drug Resistance
Surveillance Program began in 1998 [18]. Rates of TDR
were similar across all classes of drugs for both AHIs and
established infections. Multi-drug resistance (MDR),
defined as resistance to more than one class of drug, was
identified in one case of AHI versus two established cases,
resulting in MDR rates of 2% and 0.3%, respectively; how-
ever, this was not statistically significant.
Discussion
AHI detection in this analysis was based on the fact
that, during early seroconversion, antibody levels (as
Table 1 Comparison of acute and established HIV infections in British Columbia (N = 987)
Characteristic Acute cases
N = 61
Established cases
N = 926
P value Unadjusted OR
Mean age (Range) 38.6 (20-75 yr) 39.1 (0-81 yr) 0.75 -
Sex Male 52/61 (85.2%) 735/922 (79.7%) 0.295 1.47 [0.71, 3.04]
Ethnicity Caucasian 43/60 (71.7%) 540/853 (63.3%) 0.193 1.47 [0.82,2.61]
Aboriginal 9/60 (15.0%) 130/853 (15.2%) 0.960 0.98 [0.47, 2.04]
Other 8/60 (13.3%) 183/853 (21.5%) 0.135 0.56 [0.26, 1.21]
MSM 36/61 (59.0%) 424/926 (45.8%) 0.045 1.71 [1.01, 2.89]
IDU 15/61 (24.6%) 266/926 (28.7%) 0.488 0.81 [0.44, 1.47]
Heterosexual 12/61 (19.7%) 195/926 (21.1%) 0.797 0.92 [0.48, 1.76]
Reason for testing due to seroconversion symptoms 20/61 (32.8%) 80/926 (8.6%) 0.000 5.16 [2.88, 9.23]
Documented previous negative HIV test 49/61 (80.3%) 542/926 (58.5%) 0.001 2.89 [1.52, 5.51]
HIV subtype A1 0/49 (0.0%) 6/686 (0.9%) - -
B 47/49 (95.9%) 633/686 (92.3%) 0.574 1.97 [0.51, 7.52]
C 0/49 (0.0%) 22/686 (3.2%) - -
CRF 01_AE 2/49 (4.1%) 11/686 (1.6%) 0.201 2.61 [0.63, 10.87]
Other 0/49 (0.0%) 10/686 (1.5%) - -
Drug Resistance Class Wild type 45/49 (91.8%) 611/684 (89.3%) 0.809 1.34 [0.49, 3.69]
NRTI 2/49 (4.1%) 25/684 (3.7%) 0.878 1.12 [0.29, 4.42]
NNRTI 2/49 (4.1%) 28/684 (4.1%) 0.997 1.01 [0.26, 3.91]
PI 1/49 (2.0%) 18/684 (2.6%) 0.802 0.77 [0.13, 4.65]
MDRa 1/49 (2.0%) 2/684 (0.3%) 0.064 7.10 [0.92, 55.44]
a. These are included in the totals for each class.
Abbreviations: IDU - injection drug user; MDR - multi-drug resistant; MSM - men who have sex with men; NNRTI - non-nucleoside reverse transcriptase inhibitor;
NRTI - nucleoside reverse transcriptase inhibitor; PI - protease inhibitor
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reflected by instrument signals) are low and these speci-
mens are typically WB non-reactive or indeterminate
and p24 antigen reactive. Using this approach, we were
able to confirm AHI in 6.2% of all newly identified HIV
cases during the analysis period. There were 57 AHI
cases that had a reactive EIA and a non-reactive or
indeterminate WB result. In addition, there were four
AHI cases identified by p24 antigen testing following a
non-reactive screening EIA. These pre-seroconversion
cases are identified when providers specifically request
p24 antigen testing to help rule out HIV seroconversion
syndrome. Systematic pre-seroconversion screening
using p24 antigen or pooled NAT testing would likely
identify additional such cases.
Given the overall low prevalence of HIV infection
among those tested in BC (approximately 0.2%) and the
fact that pooled NAT screening of HIV seronegative
samples is not performed, the 6.2% yield of AHI is quite
high compared with the 3.95% yield from the North
Carolina population-based screening programme, which
used pooled NAT to test first-generation EIA negative
specimens [12].
Two reports have suggested AHI detection thresholds
that would support the use of population-based pooled
NAT screening. The 0.2% HIV prevalence rate among
those tested for HIV in BC is below the 0.55% threshold
suggested by Simpson et al for the cost-effective use of
this strategy [19]. Furthermore, our yield of approxi-
mately one AHI per 10,000 specimens screened is less
than the one AHI case per 1000 antibody negative sam-
ples screened by pooled NAT that has also been sug-
gested as a guideline for implementation of universal
pooled NAT screening [15]. Although we did not per-
form pooled NAT testing on EIA negative specimens,
we consider it most unlikely that this approach would
have detected 10-fold more AHI cases. While cost-effec-
tiveness studies based on US data may not be directly
applicable to HIV screening in Canada, we conclude
that a targeted rather than universal pooled NAT
screening strategy would be more appropriate for BC
[14].
Comparative demographic analysis of the AHI and
established HIV cases suggest criteria for targeted AHI
screening. First, AHI cases were more likely to occur
among repeat testers with a documented previous nega-
tive HIV test. Repeat testing may occur more frequently
in at-risk individuals who may test soon after risk. This
finding could be an underestimate as individuals who
previously tested elsewhere, as well as those repeat tes-
ters who use inconsistent identifiers, will not have been
identified. This suggests that future testing campaigns
should encourage repeat testers, especially those at high
risk, to sustain regular testing practices and to test fol-
lowing known and/or perceived risk.
Second, a high proportion of AHI cases had a reason
for testing due to seroconversion symptoms. This infor-
mation is sought from healthcare providers or from
cases directly during follow up of new positive HIV
tests. It is unlikely that all the providers asked for or
were informed by their patients about seroconversion
symptoms, but these symptoms may be ascertained
more frequently by experienced HIV providers working
with at-risk populations. Furthermore, at-risk individuals
may be more knowledgeable about symptoms of AHI
and seek out testing. Thus, this important predictor of
AHI is likely under-represented in the AHI cases identi-
fied in our analysis. This association of seroconversion
symptoms and AHI supports recommendations to edu-
cate providers to request specific testing for AHI [20],
in addition to routine HIV screening, as soon as symp-
toms are identified. Educational reinforcement is also
required for providers in settings where AHI is fre-
quently observed, as even these providers may fail to
consider the diagnosis of AHI [9]. The use of p24 anti-
gen tests to detect AHI among outpatients with fever
and other viral symptoms, regardless of HIV risk factors,
has been shown to be cost effective [21] and providers
working with at-risk populations should adopt a very
high index of suspicion with respect to seroconversion
symptoms, which are usually non-specific.
Third, while AHI cases were not shown to be signifi-
cantly more frequent among MSM in the multivariate
analysis, 65% of the AHI cases with seroconversion
symptoms were MSM. Given that MSM represented
47% of all new HIV infections during the analysis per-
iod, we recommend that priority be given to educating
MSM and their providers about the importance of sero-
conversion symptoms as an indicator of AHI. Other stu-
dies, including targeted screening in sexually transmitted
infection clinics [11], a multi-site study in six US cities
[22] and a US Centers for Disease Control study in
three public health settings [14], have also documented
Table 2 Univariate and multivariable logistic regression analysis for factors associated with acute HIV infection
Characteristic Unadjusted OR (95% CI) Adjusted OR (95% CI)
Male sex 1.47 (0.71, 3.04) 1.01 (0.43, 2.37)
MSM 1.71 (1.01, 2.89) 1.41 (0.76, 2.63)
Reason for testing due to seroconversion symptoms 5.16 (2.88, 9.23) 4.35 (2.39, 7.91)
Documented previous negative HIV test 2.89 (1.52, 5.51) 2.59 (1.35, 4.99)
Steinberg et al. Journal of the International AIDS Society 2011, 14:39
http://www.jiasociety.org/content/14/1/39
Page 4 of 7
high proportions of MSM among AHI cases. These and
our own findings support recommendations for targeted
AHI screening among MSM [14,15], in particular those
MSM with seroconversion symptoms.
Since HIV subtyping and TDR testing are routinely
performed on new HIV cases, we assessed whether
there were differences in HIV subtype distribution and
TDR rates between AHI and established cases. If TDR
rates are relatively constant over time, we would expect
the rates in individuals with AHI to be the same as for
established cases [23-25]. TDR rates among our AHI
cases are consistent with those reported for acute and
recent infections from the United States and Europe
[26-31]. In contrast, TDR rates among acute and recent
infections in Thailand and Singapore (0% and 1.7%,
respectively) are lower than those we observed [32,33].
Among individuals in BC undergoing antiretroviral ther-
apy, the incidence of drug resistance has steadily
declined since 1996 [34]. No statistically significant dif-
ferences in subtype or TDR rates, including MDR, were
observed. However, given the small AHI sample size,
our analysis may have been underpowered.
Our data analysis reflects a convenience sample of
individuals who chose to undergo HIV testing or were
referred for testing by their healthcare provider, and p24
testing of EIA negative individuals only occurred when
specifically requested. This limits the generalizability of
our findings in determining the value of AHI screening
as a health policy. Other limitations include the limited
capacity of the provincial surveillance database to
describe features of individuals with a new positive HIV
test. Geographic areas where AHI cases are concen-
trated has been shown by others to be useful to identify
sites for targeted AHI screening [13], but we did not
analyze this variable since the surveillance database cap-
tures only the location of the healthcare provider who
ordered the test.
In addition, we were not able to link co-sexually trans-
mitted infection (STI) status and/or history of previous
STIs to AHI cases. Previous studies have shown high
yields of AHI with targeted screening in STI clinics and
we expect that our AHI cases would also be more likely
to have a history of STIs and/or a current STI at the
time of HIV diagnosis. Shepard et al emphasize that the
majority of AHI cases detected in their STI clinic study
were found at one STI clinic, of which approximately
one-third of patients identified as MSM [35]. This sup-
ports our consideration to prioritize STI clinic sites that
reach out to MSM and other high-risk populations for
targeted AHI screening.
We cannot rule out the possibility that some of our
AHI cases represent late-stage disease, at which time
p24 antigen may be detectable and waning antibodies
may result in an indeterminate WB. Two presumptive
AHI cases were classified as established infections
because AIDS was reported within 12 months of HIV
diagnosis. However, delays in and incomplete AIDS case
reporting may have resulted in an overestimation of the
number of AHI cases as a result of misclassification of
late-stage disease.
Conclusions
There have been calls for more rigorous cost-effective-
ness studies to inform AHI screening strategies [11,14].
We believe that our study provides insights for a tar-
geted screening strategy to enhance detection of AHI in
BC. Our results confirm that we should continue to
investigate EIA reactive, and WB indeterminate or non-
reactive, results and possibly switch from p24 antigen
testing to the more sensitive NAT to detect AHI.
Further, we should target testing sites reaching out to
MSM and consider testing with an optimally designed
pooled NAT protocol [36]. Our findings support our
collaboration with community-based initiatives in BC to
promote awareness of AHI and offer enhanced AHI
screening to MSM [37]. This includes developing risk
profile protocols for referring persons with non-reactive
point-of-care HIV test results to undergo pooled NAT
testing.
Our results also encourage us to increase and sustain
educational initiatives for healthcare providers request-
ing HIV tests. The key messages are to promote a high
index of suspicion about seroconversion illness symp-
toms, especially in high-risk patients, and to act on this
through requests for AHI screening, and to inquire
about previous HIV testing to inform similar requests
for AHI screening.
Every HIV infection identified beyond the AHI stage is
a missed opportunity to promote risk reduction when
transmission dynamics are favourable for onward trans-
mission. Targeted screening initiatives to enhance detec-
tion of AHI are a logical public health response to the
HIV epidemic. Prevention programmes for persons with
newly diagnosed HIV infection need to be ready to
respond to individuals with AHI once identified [11].
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